Pharmacogenetic considerations in antiplatelet therapy
Publication
, Journal Article
Gurbel, PA; Rout, A; Tantry, US
Published in: Expert Review of Precision Medicine and Drug Development
July 3, 2020
Duke Scholars
Published In
Expert Review of Precision Medicine and Drug Development
DOI
EISSN
2380-8993
Publication Date
July 3, 2020
Volume
5
Issue
4
Start / End Page
235 / 238
Citation
APA
Chicago
ICMJE
MLA
NLM
Gurbel, P. A., Rout, A., & Tantry, U. S. (2020). Pharmacogenetic considerations in antiplatelet therapy. Expert Review of Precision Medicine and Drug Development, 5(4), 235–238. https://doi.org/10.1080/23808993.2020.1768844
Gurbel, P. A., A. Rout, and U. S. Tantry. “Pharmacogenetic considerations in antiplatelet therapy.” Expert Review of Precision Medicine and Drug Development 5, no. 4 (July 3, 2020): 235–38. https://doi.org/10.1080/23808993.2020.1768844.
Gurbel PA, Rout A, Tantry US. Pharmacogenetic considerations in antiplatelet therapy. Expert Review of Precision Medicine and Drug Development. 2020 Jul 3;5(4):235–8.
Gurbel, P. A., et al. “Pharmacogenetic considerations in antiplatelet therapy.” Expert Review of Precision Medicine and Drug Development, vol. 5, no. 4, July 2020, pp. 235–38. Scopus, doi:10.1080/23808993.2020.1768844.
Gurbel PA, Rout A, Tantry US. Pharmacogenetic considerations in antiplatelet therapy. Expert Review of Precision Medicine and Drug Development. 2020 Jul 3;5(4):235–238.
Published In
Expert Review of Precision Medicine and Drug Development
DOI
EISSN
2380-8993
Publication Date
July 3, 2020
Volume
5
Issue
4
Start / End Page
235 / 238